A number of research breakthroughs in molecular imaging and molecular-targeted treatments of thyroid cancer are showing signs of expansion into the clinic, according to a review in the March issue of The Lancet.

The amyloid imaging agent F-18 florbetaben has been moving forward in clinical trials for the diagnosis of Alzheimer’s disease. The up and coming F-18 florbetaben is showing signs of similar effectiveness, according to research published in the May issue of The Journal of Nuclear Medicine that presented a dynamic model of amyloid imaging using the tracer.

SHINE Medical Technologies, Inc. (SHINE), a Wisconsin-based company dedicated to being the world leader in safe, clean, and affordable production of medical isotopes and cancer treatment elements, has submitted its Construction Permit application to the Nuclear Regulatory Commission (NRC). This submittal is the first formal step by SHINE in seeking an NRC permit to begin construction of its medical isotope facility in Janesville, Wisconsin.

Advanced Medical Isotope Corporation (AMIC) has entered into a strategic alliance with GSG International to collaborate in the joint development of technologies for the production of medical isotopes and the marketing and distribution of related isotopes, equipment and services.

GE is responding to the call for advanced and affordable care with two new 1.5T MR scanners — the Optima MR360 Advance and Brivo MR355 Inspire — designed to produce images that compare well with 3T systems, but at a reduced total cost of ownership for the facility

The short-term prognostic benefit of myocardial perfusion scintography (MPS) is well established, and the technique also delivers long-term value up to five years after initial imaging, according to a study in the Journal of Nuclear Cardiology. 

Patients with advanced education showing early signs of Alzheimer’s disease (AD) were found to be less vulnerable to neural damage associated with the disease, according to a review in the March publication of Neurology.

 A March 22 teleconference between the Society of Nuclear Medicine and Molecular Imaging (SNMMI), Alzheimer's Association and other stakeholders discussed new appropriate use recommendations concerning amyloid imaging for the evaluation of Alzheimer's disease to be reviewed by CMS.